A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.
The 52-week Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) investigated the gastrointestinal and cardiovascular safety profile of lumiracoxib 400 mg once daily compared with 2 traditional nonsteroidal anti-inflammatory drugs (NSAIDs): ibuprofen 800 mg 3 times daily and naproxen 500 mg twice daily. Data from TARGET were analyzed to examine the effect of lumiracoxib compared with ibuprofen and naproxen on blood pressure (BP), incidence of de novo and aggravated hypertension, prespecified edema events, and congestive heart failure. Lumiracoxib resulted in smaller changes in BP as early as week 4. Least-squares mean change from baseline at week 4 for systolic BP was +0.57 mm Hg with lumiracoxib compared with +3.14 mm Hg with ibuprofen (P<.0001) and +0.43 with lumiracoxib compared with +1.80 mm Hg with naproxen (P<.0001). In conclusion, the use of lumiracoxib and traditional NSAIDs results in differing BP changes; these might be of clinical relevance.
Farkouh
Michael E
ME
Clinical Trials Unit, Mount Sinai Cardiovascular Institute, New York, NY 10029, USA. michael.farkouh@mssm.edu
Verheugt
Freek W A
FW
Ruland
Sean
S
Kirshner
Howard
H
Jeger
Raban
R
Gitton
Xavier
X
Krammer
Gerhard
G
Stricker
Kirstin
K
Sallstig
Peter
P
Mellein
Bernhard
B
Matchaba
Patrice
P
Chesebro
James H
JH
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D003404:Creatinine / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004008:Diclofenac / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000008:administration & dosage / Q000494:pharmacology*; D010147:Pain Measurement
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D004008:Diclofenac; D009288:Naproxen; D003404:Creatinine; C473384:lumiracoxib; D007052:Ibuprofen
Clin Pharmacokinet. 2004;43(7):467-78
15139795
Scand J Rheumatol. 2004;33(1):1-6
15124935
Am J Ther. 2001 Mar-Apr;8(2):85-95
11304662
Clin J Pain. 2005 Mar-Apr;21(2):147-53
15722808
Am J Cardiol. 2002 Nov 1;90(9):959-63
12398962
Clin Ther. 2005 Jan;27(1):64-77
15763607
Clin Pharmacol Ther. 2002 Jul;72(1):50-61
12152004
Lancet. 2004 Aug 21-27;364(9435):665-74
15325831
Expert Opin Drug Saf. 2006 Jan;5(1):83-94
16370958
J Rheumatol. 2003 Apr;30(4):714-9
12672188
J Hypertens Suppl. 2002 Sep;20(6):S3-9
12683421
Arch Intern Med. 1993 Feb 22;153(4):477-84
8435027
Eur Heart J. 2007 Jun;28(12):1462-536
17562668
Curr Med Res Opin. 2005 Apr;21(4):517-26
15899100
Aliment Pharmacol Ther. 2004 Jul 1;20(1):51-63
15225171
Am J Nephrol. 2001 Jan-Feb;21(1):1-15
11275626
Arch Intern Med. 2005 Mar 14;165(5):490-6
15710786
Ann Intern Med. 1994 Aug 15;121(4):289-300
8037411
Bull World Health Organ. 2003;81(9):646-56
14710506
Am J Manag Care. 2002 Oct;8(15 Suppl):S383-91
12416788
Expert Rev Clin Immunol. 2005 May;1(1):37-45
20477653
Lancet. 2004 Aug 21-27;364(9435):675-84
15325832
Am J Hypertens. 2000 Nov;13(11):1161-7
11078175